Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that its leadership team will hold one-on-one investor meetings and deliver a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston.
The fireside chat is scheduled for Monday, November 10, 2025 at 8:30 AM ET. A live webcast will be available and archived for 90 days via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 12 Alerts
On the day this news was published, CRVS gained 3.61%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.1% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $629M at that time.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET.
A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
FAQ
When will Corvus Pharmaceuticals (CRVS) present at the Guggenheim Healthcare Innovation Conference?
How can investors watch the Corvus (CRVS) fireside chat webcast?
Will Corvus (CRVS) leadership meet with investors at the Guggenheim conference?
Where is the Guggenheim 2nd Annual Healthcare Innovation Conference taking place for Corvus (CRVS)?
How long will the Corvus (CRVS) webcast be available after the Guggenheim presentation?
Where on the Corvus site is the Guggenheim webcast hosted?
